Table 1.
Characteristics of included articled in network meta-analysis.
| First author and year | Country | Study design | Sample size and population | Clinical stages | Panel | Number of panel components | Sensitivity | Specificity | Accuracy | Method of chemical evaluation | Type of sample | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S Zajkowska, M. 2016 [59] | Poland | Case-control | 240 Bc: 120 B: 60 H: 60 Median age (range) 54 (34–72) |
I: 29 II: 30 III: 31 IV: 30 |
VEGF + CA 15-3 M-CSF + CA 15-3 VEGF + M-CSF + CA 15-3 VEGF+ M-CSF∗ |
2 2 3 2 VEGF M-CSF CA 15-3 |
95 (E) 88.3 (E) 95 (E) 87 (E) 76.25 60 83.75 |
65 67.5 57.5 76 85 90 75 |
77.8 (E) 76.4 (E) 73.5 (E) 80.7 (E) |
ELISA CMIA |
Plasma | 11 |
| Ikemura, M. 2017 [54] | Japan | Cohort | 178 Bc: 94 H: 84 56 ± 12.5 26-88 |
I: 42 II: 14 III: 20 |
TF1+TF2+TF3 TF1 TF2 TF3 |
3 | 90 67 78 87 |
93 68 79 48 |
91.4 | ELISA | Serum | 11 |
| Swellam, M. 2014 [36] | Egypt | Case-control | 160 Bc80 B40 H40 35.6(17-67) |
I: 46 III/II: 34 |
MMP-9/TIMP-1 (ratio) |
2 MMP-9 TIMP-1 |
97.5 97.5 95 |
95 95 92.5 |
96.25 | ELISA | Serum | 11 |
| Ławicki, Sławomir 2016 [57] | Poland | Case-control | 200 Bc100 B50 H50 48 (20-78) |
I/II/III: 77 IV: 23 (with metastases) |
VEGF +CA15-3 | 2 VEGF CA 15-3 |
76 (E) 61 65 |
90 96 96 |
84.1 (E) | ELISA | Plasma | 11 |
| Lawicki, S. 2017 [58] | Poland | Case-control | 200 Bc100 B50 H50 48 (20-78) |
I/II/III: 77 IV: 23 |
VEGF+ CA 15-3 | 2 VEGF CA 15-3 |
78 (E) 60 64 |
90 95 95 |
84.7 (E) | ELISA | Plasma | 11.5 |
| Tjandra, JJ 1988 [60] |
Australia | Case-control | 161 Bc109 B31 H21 |
I: 32 II: 24 III/IV: 53 |
MSA + B2m | 2 MSA B2m |
88 (E) 88 39 |
90 95 90 |
88.5 (E) | Radioimmunoassay + ELISA | Serum | 12 |
| Ławicki, S 2013 [55] | Poland | Case-control | 190 Bc110 B40 H40 44 (30-78) |
I: 25 II: 35 III: 25 IV: 25 (with metastases) |
M-CSF + CA15-3 | 2 M-CSF CA 15-3 |
68 (E) 60 53 |
90 95 95 |
78.6 (E) | ELISA | Plasma | 11 |
| Ławicki, Sławomir 2013 [56] | Poland | Case-control | 200 Bc100 B50 H50 51 (40–70) |
I/II/III: 75 IV: 25 (with metastases) |
VEGF+ CA 15-3 M-CSF+ CA 15-3 VEGF + M-CSF VEGF+ M-CSF+ CA 15-3 |
2 2 2 3 VEGF M-CSF CA 15-3 |
63 (E) 57 (E) 60 (E) 68 (E) 44 53 36 |
86 86 86 78 92 94 92 |
76.4 (E) 73.9 (E) 75.2 (E) 73.8 (E) |
ELISA | Plasma | 11 |
| Metwally, Fatehya M 2011 [61] | Egypt | Case-control | 65 Bc44 H21 36 (23–56) |
I: 21 II: 14 III: 9 |
CA 15.3 + IL-18 | 2 CA 15.3 IL-18 |
88.6 52.2 77.2 |
100 100 100 |
92.3 | MEIA + ELISA + Colorimetric method | Serum | 10.5 |
BC: breast cancer; B: benign; H: healthy; E: early stages (I, II, III); ELISA: the enzyme-linked immunosorbent assay; CMIA: luminescent microparticle immunoassay; MEIA: microparticle enzyme immunoassay. ∗It was made based on linear combination [35]. The scoring system based on the CASP checklist (specified for diagnostic studies) was applied for all studies.